# A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

> **NCT03758417** · PHASE2 · TERMINATED · sponsor: **Nanjing Legend Biotech Co.** · enrollment: 123 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** LCAR-B38M CAR-T Cell

## Key facts

- **NCT ID:** NCT03758417
- **Lead sponsor:** Nanjing Legend Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-23
- **Primary completion:** 2025-07-10
- **Final completion:** 2025-10-20
- **Target enrollment:** 123 (ACTUAL)
- **Why stopped:** The study was terminated early due to a strategic realignment of the sponsor's business plan, not related to safety, efficacy, or data integrity concerns.
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758417, "A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT03758417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*